Rizvanovic Husref and Kim Kyoungtae*

Department of Biology, Missouri State University, Springfield, Missouri, USA

*Corresponding Author: Kim Kyoungtae, Department of Biology, Missouri State University, Springfield, Missouri, USA.

Received: May 20, 2021 ; Published: June 11, 2021

Abstract

Although current therapies for treating thyroid cancer offers good prognosis, there is an unmet need for better alternative anti-cancer drugs for treatment. Studies have shown that platinum based chemicals such as Cisplatin offer decent treatment options, but can also lead to severe side effects as well as develop a resistance. Given that cyanoximes are great ligands and that metals such as platinum offer good anti-proliferative and cytotoxic abilities, we investigated the role of a novel platinum-based cyanoximate in the treatment of thyroid cancer. Stage 4 thyroid cancer cell line, ML-1, was used in the present study to test the effects on cell viability and proliferation after treatment of Cisplatin and Pt(DECO)₂. Changes in the levels of superoxide were also tested and compared with non-treated cells. Lastly, presentation of cell death was recorded after the treatment. After 24 hours of treatment at concentrations of 1.0 mM of Pt(DECO)₂, we noticed drastic reduction in cell viability (F = 45.77, p < 0.0001), superoxide levels (F = 28.57, p = 0.0001), and an increase in cell death. These results suggest that this cyanoximate-induced cell death may work similarly to Cisplatin-based cell death. This in vitro study demonstrated the efficacy of the novel cyanoximate Pt(DECO)₂ in treating thyroid cancer. Further studies are needed to delineate the effectiveness of this treatment in vivo and with other cancer cell lines.

Keywords: Cisplatin; Platinum; Pt(DECO)₂; Thyroid Cancer; ML-1; Apoptosis; ROS; XTT

References

1. Morris LG., et al. “The increasing incidence of thyroid cancer: the influence of access to care”. Thyroid 23 (2013): 885-891.
2. Rahib L., et al. “Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the united states”. Cancer Research 11 (2014): 2913-2921.
3. Nickel B., et al. “Health-Related Quality of Life After Diagnosis and Treatment of Differentiated Thyroid Cancer and Association With Type of Surgical Treatment”. JAMA Otolaryngology - Head and Neck Surgery 3 (2019): 231-238.
4. Schlumberger M., et al. “Lenvatinib versus Placebo in Radioiodine Refractory Thyroid Cancer”. The New England Journal of Medicine 7 (2015): 621-630.
5. Schlumberger M., et al. “Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma”. The Journal of Clinical Endocrinology and Metabolism 4 (1986): 960-967.
6. Frezza M., et al. “Novel Metals and Metal Complexes as Platforms for Cancer Therapy”. Current Pharmaceutical Design 16 (2010): 18131825.
7. Yimit A., et al. “Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs”. Nature Communication 10 (2019): 309.
8. Eddings D., et al. “First Bivalent Palladium and Platinum Cyanoximates: Synthesis, Characterizations, and Biological Activity”. Inorganic Chemistry 13 (2004): 3894-3909.
9. Dasari S and Tchounwou PB. “Cisplatin in Cancer Therapy: Molecular Mechanisms of Action”. European Journal of Pharmacology 740 (2014): 364-378.
10. Bergamo A and Sava G. “Linking the future of anticancer metal-complexes to the therapy of tumour metastases”. Chemical Society Reviews 24 (2015): 8818-8835.
11. Ndagi U., et al. “Metal complexes in cancer therapy - an update from drug design perspective”. Drug Design, Development and Therapy 11 (2017): 599-616.
12. Ratcliff J., et al. “Part 1: Experimental and theoretical studies of 2-cyano-2-isonitroso- N-piperidynylacetamide (HPiPCO), 2-cyano-2-isonitroso- N-morpholylacetamide (HMCO) and their Pt- and Pdcomplexes”. Inorganica Chimica Acta 285 (2012): 1-20.
13. Dannen SD., et al. “New in vitro highly cytotoxic platinum and palladium cyanoximates with minimal side effects in vivo”. Journal of Inorganic Biochemistry (2020) :208.
14. Piccinini F., et al. “Cell counting and viability assessment of 2d and 3d cell cultures: expected reliability of the trypan blue assay”. Biological Procedures Online1 (2017): 8.
15. Yusof F., et al. “Antioxidants effects of Platinum Nanoparticles: A Potential Alternative Treatment to Lung diseases”. Journal of Applied Pharmaceutical Science 7 (2015): 140-145.
16. B Halliwell. “Antioxidants in human health and disease”. Annual Review of Nutrition 6 (1996): 33-50.
17. Shibuya S., et al. “Palladium and Platinum Nanoparticles Attenuate Aging- Like Skin Atrophy Via Antioxidant Activity in Mice”. PloS One10 (2014): 109-288.
18. Li R., et al. “Defining ROS in Biology and Medicine”. Reactive Oxygen Species (Apex) 1.1 (2016): 9-21.
19. Takamiya M., et al. “Neurological and Pathological Improvements of Cerebral Infarction in Mice with Platinum Nanoparticles”. Journal of Neuroscience Research7 (2011): 1125-1133.
20. Goldar S., et al. “Molecular mechanisms of apoptosis and roles in cancer development and treatment”. Asian Pacific Journal of Cancer Prevention 6 (2015): 2129-2144.
21. Danial NN and Korsmeyer SJ. “Cell Death: Critical Control Points”. Cell 2 (2004): 205-219.
22. Pfeffer CM and Singh ATK. “Apoptosis: A Target for Anticancer Therapy”. International Journal of Molecular Sciences 2 (2018): 448.
23. Gong C., et al. “Hepatotoxicity and pharmacokinetics of cisplatin in combination therapy with a traditional Chinese medicine compound of Zengmian Yiliu granules in ICR mice and SKOV-3-bearing nude mice”. BMC Complementary and Alternative Medicine 15 (2015): 283.

Citation

Citation: Rizvanovic Husref and Kim Kyoungtae. “Novel Cyanoximate Pt (DECO)2 as an Anti-Cancer Drug Using ML1 Thyroid Cancer Cells”. Acta Scientific Microbiology 4.7 (2021): 50-56.

Copyright

Copyright: © 2021 Rizvanovic Husref and Kim Kyoungtae. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.